SRPT - Sarepta Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
+2.98 (+3.20%)
At close: 4:00PM EDT

95.98 0.00 (0.00%)
After hours: 5:10PM EDT

Stock chart is not supported by your current browser
Previous Close93.00
Bid90.00 x 1000
Ask95.50 x 1200
Day's Range91.75 - 98.29
52 Week Range72.05 - 158.80
Avg. Volume927,060
Market Cap7.397B
Beta (5Y Monthly)2.04
PE Ratio (TTM)N/A
EPS (TTM)-9.71
Earnings DateMay 05, 2020 - May 10, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est192.24
  • GlobeNewswire

    Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Sarepta Therapeutics, Inc. (SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on March 31, 2020 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to thirteen individuals hired by Sarepta in March 2020. The employees received, in the aggregate, options to purchase 13,790 shares of Sarepta's common stock, and in the aggregate, 6,915 restricted stock units (“RSUs”). The options have an exercise price of $97.82 per share, which is equal to the closing price of Sarepta's common stock on March 31, 2020 (the “Grant Date”).

  • Sarepta Therapeutics (SRPT) Down 8% Since Last Earnings Report: Can It Rebound?

    Sarepta Therapeutics (SRPT) Down 8% Since Last Earnings Report: Can It Rebound?

    Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Thomson Reuters StreetEvents

    Edited Transcript of SRPT earnings conference call or presentation 26-Feb-20 9:30pm GMT

    Q4 2019 Sarepta Therapeutics Inc Earnings Call

  • Do Hedge Funds Love Sarepta Therapeutics Inc (SRPT)?
    Insider Monkey

    Do Hedge Funds Love Sarepta Therapeutics Inc (SRPT)?

    Coronavirus is probably the 1 concern in investors’ minds right now. It should be. On February 27th we published this article and predicted that a US recession is imminent and US stocks will go down by at least 20% in the next 3-6 months. We also told you to short the market ETFs and buy long-term […]

  • Sarepta Therapeutics, Inc. Analysts Are Cutting Their Estimates: Here's What You Need To Know
    Simply Wall St.

    Sarepta Therapeutics, Inc. Analysts Are Cutting Their Estimates: Here's What You Need To Know

    It's been a sad week for Sarepta Therapeutics, Inc. (NASDAQ:SRPT), who've watched their investment drop 13% to US$108...

  • Sarepta (SRPT) Q4 Loss Widens Y/Y, Revenues Miss Estimates

    Sarepta (SRPT) Q4 Loss Widens Y/Y, Revenues Miss Estimates

    Sarepta (SRPT) reports wider year-over-year loss. However, revenues increase year over year.

  • GlobeNewswire

    Sarepta Therapeutics Announces Third Year of Route 79, The Duchenne Scholarship Program

    Sarepta Therapeutics, Inc. (SRPT), the leader in precision genetic medicine for rare diseases, today announced that the website for Route 79, The Duchenne Scholarship Program, is officially open and accepting applications. Academic scholarships of up to $5,000 will be awarded to up to 20 individuals chosen by an independent committee of Duchenne community members based on an applicant’s community involvement, personal essay and recommendation letter. The Route 79 program is designed to help students with Duchenne pursue their post-secondary educational goals.

  • GlobeNewswire

    Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2019 Financial Results and Recent Corporate Developments

    CAMBRIDGE, Mass., Feb. 26, 2020 -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for.

  • Analysts Estimate Sarepta Therapeutics (SRPT) to Report a Decline in Earnings: What to Look Out for

    Analysts Estimate Sarepta Therapeutics (SRPT) to Report a Decline in Earnings: What to Look Out for

    Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire

    Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2019 Financial Results and Recent Corporate Developments on February 26, 2020

    Sarepta Therapeutics, Inc. (SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year 2019 financial results after the Nasdaq Global Market closes on Wednesday, February 26, 2020. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its fourth quarter and full-year 2019 financial results and to provide a corporate update. The conference call may be accessed by dialing (844) 534-7313 for domestic callers and (574) 990-1451 for international callers.

  • Sarepta Therapeutics (NASDAQ:SRPT) Has Debt But No Earnings; Should You Worry?
    Simply Wall St.

    Sarepta Therapeutics (NASDAQ:SRPT) Has Debt But No Earnings; Should You Worry?

    The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

  • Business Wire

    Shareholder Alert: Robbins LLP Reminds Investors Sarepta Therapeutics, Inc. (SRPT) Sued for Misleading Shareholders

    Shareholder rights law firm Robbins LLP reminds investors that a purchaser of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) filed a class action complaint for alleged violations of the Securities Exchange Act of 1934 between September 6, 2017 and August 19, 2019. Sarepta Therapeutics focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine for the treatment of rare diseases. Sarepta's products pipeline includes its drug golodirsen for the treatment of duchenne muscular dystrophy ("DMD").

  • Vanguard Health Care Fund Adds 4 Stocks to Portfolio in 4th Quarter

    Vanguard Health Care Fund Adds 4 Stocks to Portfolio in 4th Quarter

    3 of the fund’s new holdings are biotech companies Continue reading...

  • BTIG: New Data Could Propel These 3 Biotech Stocks Higher in 2020

    BTIG: New Data Could Propel These 3 Biotech Stocks Higher in 2020

    For those who like patterns, biotech names’ growth stories tend to look remarkably similar. These stocks are less reliant on earnings reports and more on a few select markers which can decide what direction they will take in the near-term. A favorable outcome from a regulatory committee or promising data from a clinical trial can send the stock soaring. Conversely, rejection or disappointing readouts can send the company’s share price tumbling down. While they present possible mercurial upside, these tickers aren’t for the faint of heart because although the patterns usually play out, the direction they might take is very hard to predict.So, how should investors choose which biotechs to invest in? There are different strategies, of course, but one trusted way is to listen to the experts. Investment bank BTIG is a well-known name on the Street, housing several top analysts. The company has identified three companies in the sector that will present new data over the coming months, and BTIG analysts think positive results can propel each of them forward.Using the Stock Comparison tool from TipRanks, a company that tracks and measures the performance of analysts, we were able to zero in on their choices and find out why the firm finds them so compelling. Let’s get familiar with the data at hand. Sarepta Therapeutics (SRPT)Let’s start off with a good example of the impact regulatory forces can have on a stock. Sarepta Therapeutics made headlines towards the end of 2019, when the FDA approved Vyondys 53, the company’s treatment for Duchenne muscular dystrophy (DMD) patients with exon 53 mutations. The approval came as a surprise as only a few months earlier, Sarepta received the dreaded CRL (complete response letter) from the FDA following its original submission. As is de rigueur in the sector, Sarepta stock responded to the announcement by soaring over 30% in a day.In addition to the recently approved drug, the genetic disorder-focused biotech has a robust pipeline, with gene therapy programs in DMD and LGMD (Limb Girdle Muscular Dystrophy). BTIG’s Tim Chiang believes the company is steadily progressing with these key programs.The analyst said, “We believe SRPT is making progress on the gene therapy manufacturing front, and has achieved yields sufficient to begin study 301 (which we think could enroll up to a hundred or more patients). We believe SRPT plans to provide an interim look at data from this study in ~15 patients dosed (evaluating expression levels at ~3 months post dosing). In LGMD2E, SRPT has dosed two patients in the higher dose cohort, with a third patient to be dosed shortly. We expect a data read out from this high dose arm in early 2Q.”Chiang expects that US gene therapy sales in the DMD market will reach a peak in 2024, with the figure landing at roughly $2 billion. There are three companies currently in the race to develop gene therapies for the treatment of DMD; Sarepta, according to the analyst, is leading the way and could be the first to enter the US market with its gene therapy for DMD in the second half of 2021.Chiang added, “We think one of the key differences among the 3 micro-dystrophin gene therapy programs in the clinic are that both Solid Biosciences (SLDB, Neutral) and Pfizer have studies where ascending dose cohorts are being utilized. In contrast, Sarepta’s study incorporates just one dose (2E14 vg/kg).”So, what does this mean? It means Chiang kept his Buy rating on Sarepta, along with a price target of $190. Should the target be met, investors stand to see a handsome 64% gain over the next year. (To watch Chiang’s track record, click here)The Street, too, is bullish on the DMD fighter. A Strong Buy consensus rating breaks down into 18 Buys and a single Hold. The average price target comes in at $204.33 and indicates potential upside of 76%. (See Sarepta stock analysis on TipRanks) IMV Inc. (IMV)IMV’s market performance in 2019 was a disappointing affair; The stock lost 39% of its value along the way. By contrast, 2020’s performance so far has been the exact opposite - and some. The stock is up by 58% year-to-date. According to BTIG’s Thomas Shrader, there is more to come, too.The cancer fighter’s lead candidate is DPX-Survivac, which targets the surviving TAA (tumor associated antigen) that is overexpressed in more than 20 different types of cancers. Clinical data so far has been promising, with long disease-free intervals in the ovarian cancer (OC) adjuvant setting and compelling treatment response rates in both OC and DLBCL (diffuse large B-cell lymphoma). Important DPX-Survivac data is expected this quarter which Shrader notes “could greatly de-risk the current programs and potentially demonstrate the utility of the low-COGS DPX platform to deliver many other TAAs and neoantigens.”The 5-star analyst added, “The drug has shown robust and prolonged CD8 TCell responses in the adjuvant setting and a Phase 1b/2 trial has shown a 100% DCR and 60% ORR in the subgroup of patients with non-bulky disease (tumor burden < 5 cm) most of which are platinum-resistant (few treatment options). The company expects to provide topline Phase 2 monotherapy data in mid-February 2020 that we expect to be an important catalyst for the story.”Ahead of this upcoming data readout, Shrader is siding with the bulls. The analyst initiated coverage of IMV with a Buy rating along with an $8 price target. The implication? Further gains in the shape of 75% over the next 12 months. (To watch Shrader’s track record, click here)The Street agrees. A total of 6 Buys add up to a unanimous Strong Buy consensus rating. With an average price target of $9.31, the analysts see potential upside of 104% for IMV over the coming 12 months. (See IMV stock analysis on TipRanks) Cue Biopharma Inc. (CUE)A fellow company taking the fight to cancer is Cue Biopharma. In 2019, Cue’s exceptional performance beat the market considerably. The stock added an astounding 238% to its share price throughout the year. Following such a surge, though, is this the right time to get in on this high-flying biotech?Yes, it is, according to BTIG’s Thomas Shrader. In fact, the 5-star analyst just recently initiated coverage of Cue with an emphatic Buy rating. The thumbs up comes with a price target of $26, indicating Shrader believes an additional 71% will be added to Cue’s share price over the next 12 months.So, what’s all the fuss about, then? A cure for cancer is one of modern medicine’s most coveted prizes. Cue is working on an immunotherapy platform which will assist immune systems by recognizing solid tumor cells and repeatedly attacking them until they stop working.The company’s lead candidate is CUE-101, which was developed for patients with head and neck cancer driven by human papillomavirus (HPV). Topline results from a Phase 1 trial are expected later this year, and so far, results have been promising.Shrader said, “Data to date is preclinical but the lead programs termed CUE-101 has exploited well defined subunits and demonstrated tumor antigen-specific T-cells responses without the accompanying systemic immune toxicities that characterize many competing approaches… Preclinical data confirm both robust T-Cell responses and an attractive safety profile setting the stage for clinical studies. These studies have stated (first dosing September 2019) and, based on the preclinical safety profile, will begin with doses that could be efficacious. Clinical data validating the overall approach are expected around 3Q20 and, if promising, a significant pipeline in additional applications should be de-risked.”Currently, the rest of the Street remains rather quiet on Cue, with only one other analyst chipping in with a take on the biotech’s prospects. The additional Buy recommendation means Cue receives a Moderate Buy consensus rating. The average price target comes in at $24 and implies upside potential of 58%. (See Cue Biopharma stock analysis on TipRanks)

  • Families of rare-disease patients take on drug development, but face uphill battle
    American City Business Journals

    Families of rare-disease patients take on drug development, but face uphill battle

    Frustrated with the slow pace of drug discovery and desperate to help their loved ones, untrained family members take the work into their own hands by starting biopharma companies. But few such companies have been successful.

  • Roche (RHHBY) 2019 Sales Solid on Robust Show by New Drugs

    Roche (RHHBY) 2019 Sales Solid on Robust Show by New Drugs

    Roche's (RHHBY) performance in 2019 is driven by solid strength in new drugs, which more than offset competition from biosimilars.

  • 5 'Strong Buy' Biotech Stocks to Buy for 2020

    5 'Strong Buy' Biotech Stocks to Buy for 2020

    Investors seeking out high growth for their portfolios will often turn to biotech stocks. The biotechnology industry, which has become densely populated as our understanding of living systems and organisms continues to expand, has earned a reputation on Wall Street for its explosive potential ... and high volatility.In contrast to companies in other sectors, the gains and losses in even the best biotech stocks hinge less on earnings results, and more on a few key indicators such as trial-data readouts or verdicts from regulatory agencies. Product approvals unlock vital revenues, so a single positive update can function as a catalyst that propels shares to new highs.Of course, there's a reason risk-averse investors shy away from these stocks: The opposite also holds true.Wall Street pros rightly advise a cautious approach when evaluating the biotechnology industries. We find that monitoring the analyst community can be helpful on a couple fronts: For one, we can see where the pros are putting their faith. Also, analysts can provide much-needed insight into many stocks that get little media coverage, and whose progress can be difficult to gauge unless you're a medical expert.We used TipRanks' Stock Screener tool to comb through hundreds of biotechnology stocks to identify promising picks - ones that have received enough lopsided support from analysts that they earn TipRanks' top Strong Buy consensus rating. Here, we have found five top biotech stocks with overwhelmingly bullish sentiment from the analyst community, and price-growth projections of between 28% and 82%. SEE ALSO: 8 Stock Picks Getting Hit by Coronavirus Fears

  • Biotech Hits Two-Day Skid After FDA Sheds Light On Initial Drug Rejection
    Investor's Business Daily

    Biotech Hits Two-Day Skid After FDA Sheds Light On Initial Drug Rejection

    Shares of SRPT stock toppled Thursday after U.S. regulators unveiled the concerns that led them to initially reject Sarepta Therapeutics' newest Duchenne muscular dystrophy drug, Vyondys 53.

  • GlobeNewswire

    Bragar Eagel & Squire is Investigating Certain Officers and Directors of Cardinal Health, CURO Group, Sarepta, and PG&E Corporation and Encourages Investors to Contact the Firm

    NEW YORK, Jan. 23, 2020 -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, is investigating certain officers and directors of Cardinal Health,.

  • New FDA documents shed light on agency's rejection of Sarepta drug
    American City Business Journals

    New FDA documents shed light on agency's rejection of Sarepta drug

    Patient deaths, testing concerns and “weak arguments.” Those are just a few of the issues the FDA had with Sarepta Therapeutics’s recent drug application, according to new documents released this week.

  • Are Options Traders Betting on a Big Move in Sarepta (SRPT) Stock?

    Are Options Traders Betting on a Big Move in Sarepta (SRPT) Stock?

    Investors need to pay close attention to Sarepta (SRPT) stock based on the movements in the options market lately.

  • FDA Risks Sacrificing Its Standards for Speed

    FDA Risks Sacrificing Its Standards for Speed

    (Bloomberg Opinion) -- Today’s Food and Drug Administration moves much faster than it used to. That may not always be a good thing. A review of drug approvals by the agency from researchers at Harvard Medical School released Tuesday found that the FDA is approving drugs more rapidly with weaker evidence than it did in the past. That can be beneficial when it leads to needed medicines getting to market quickly, and I believe that’s the agency’s intent. As the study’s authors highlight, however, this emphasis on speed and flexibility could be eroding standards. It may be time for a gut check.The gold standard for demonstrating efficacy — and the surest way of winning drug approval — is to demonstrate success in large, well-controlled studies that result in a hard outcome. But there are faster ways to get to market. In 1992, Congress created the accelerated approval program, which can green light medicines based on “surrogate” endpoints that predict rather than confirm benefit for patients, or those that have shown a shorter-term benefit. It’s one of several initiatives that have changed how the agency works. According to the study, 80.6% of approvals between 1995 and 1997 were supported by at least two pivotal trials. That number dropped to 52.8% between 2005 and 2017. Companies that get accelerated approval have to prove their drug works with a confirmatory trial in order to gain full approval, but there’s no hard timetable no when that must be done. Thus, drugmakers often don't hurry to conduct those tests. This is problematic at best, dangerous at worst.Here’s just one case: In 2016, Sarepta Therapeutics Inc. sought approval of a medicine to treat a rare muscle-wasting disease in young boys based on weak evidence from a tiny trial. In the face of significant public pressure, the FDA approved Exondys 51 even though one of its scientists called the treatment “an elegant placebo” in a report. Sarepta is selling the drug for over $300,000 a year but has continually delayed a confirmatory trial. It’s now years away from completion, and there have been no real consequences for the delay.When companies do complete post-approval trials, it sometimes reveals a mistake. Eli Lilly & Co.’s cancer drug Lartruvo got accelerated approval in 2016. Lilly then pulled the medicine from the market last year after a larger trial found no benefit. That’s a rare outcome, but there are many expensive drugs on the market that have never moved beyond surrogate endpoints. A study of 93 accelerated cancer drug approvals between 1992 and 2017 found that only 19 had proved to help patients live longer in a followup trial. There are some good reasons for faster approvals, as former FDA Commissioner Scott Gottlieb outlined in a Twitter response this week to a critical New York Times editorial penned on Jan. 11. Scientists are better at evaluating the safety of medicines and trial design has improved, for example. And advances have made it easier to create drugs that target small populations and have dramatic effects, Gottlieb wrote.He makes good points. But the agency arguably hasn’t found the right balance between embracing advances and maintaining a high bar. It certainly has a ways to go on post-approval follow up. America is entirely unable to control the price of new medicines; the approval of marginal drugs has financial consequences. The FDA will soon face one of its most important and controversial decisions yet. Biogen Inc. is seeking approval for the first purportedly disease-modifying Alzheimer’s drug — a medicine that could be used by millions of people and cost billions — without good evidence that it works. The agency often uses unmet need as a justification for shifting standards, and there’s no bigger unmet need than Alzheimer’s. That doesn’t justify an approval based on one failed trial and another that is a questionable success at best.The agency will have to decide whether to review or approve the medicine in the next year or so. This choice is an opportunity to resist public pressure and move back toward demanding firmer proof of efficacy before drugs hit the market. To contact the author of this story: Max Nisen at mnisen@bloomberg.netTo contact the editor responsible for this story: Beth Williams at bewilliams@bloomberg.netThis column does not necessarily reflect the opinion of Bloomberg LP and its owners.Max Nisen is a Bloomberg Opinion columnist covering biotech, pharma and health care. He previously wrote about management and corporate strategy for Quartz and Business Insider.For more articles like this, please visit us at now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

  • Does Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) CEO Pay Matter?
    Simply Wall St.

    Does Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) CEO Pay Matter?

    Doug Ingram became the CEO of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in 2017. First, this article will compare CEO...